Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GILDESS FE 1/20 vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release; norethindrone induces progestational changes in endometrium and cervical mucus, preventing ovulation and fertilization.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Prevention of pregnancy,Treatment of moderate acne vulgaris (for females ≥15 years old who have menarche and desire contraception),Oral contraceptive for women with iron deficiency anemia (as Gildess Fe 1/20 contains ferrous fumarate)
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet orally once daily for 21 days followed by 7 placebo tablets per 28-day cycle.
400 mg orally once daily with food.
Ethinyl estradiol: terminal half-life approximately 13 hours (range 10-15 h). Desogestrel: metabolized to etonogestrel; etonogestrel terminal half-life about 28 hours (range 20-40 h). Clinical context: steady-state reached within 7-10 days.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Ethinyl estradiol undergoes CYP3A4-mediated hydroxylation; norethindrone is reduced and conjugated via glucuronidation and sulfation.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Approximately 60-65% renal (as metabolites), 30-35% fecal (as metabolites and unchanged drug). Ethinyl estradiol and desogestrel metabolites are excreted primarily via urine and feces. Etonogestrel (active metabolite) is excreted mainly via feces (40%) and urine (32%).
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Ethinyl estradiol: 97-98% bound to albumin, with specific binding to sex hormone-binding globulin (SHBG). Etonogestrel: >95% bound, primarily to albumin (60-70%) and SHBG (30-40%).
98% bound to albumin
Ethinyl estradiol: apparent Vd approximately 2.5 L/kg (range 2.1-3.0 L/kg). Desogestrel: Vd for etonogestrel is about 2.0 L/kg. High Vd indicates extensive tissue distribution, including adipose and reproductive tissues.
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: Ethinyl estradiol bioavailability approximately 45-55% due to first-pass metabolism (sulfation and glucuronidation). Desogestrel: prodrug, bioavailability of etonogestrel is about 76-84% after oral dose. No other relevant routes.
Oral: 85-90%; IM: 95-100%
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to potential for fluid retention.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Caution in moderate impairment (Child-Pugh class B) due to altered hormone metabolism; use alternative methods if possible.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Approved for postmenarchal adolescents; dosing same as adults: one tablet orally once daily for 21 days followed by 7 placebo tablets.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not typically indicated for postmenopausal women due to ineffectiveness; if used in appropriate patients, no dose adjustment required but monitor for thromboembolic risks.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and smoking intensity (≥15 cigarettes/day) and is significant in women >35 years old. Women >35 who smoke should not use this product.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Thrombotic disorders (thrombophlebitis, venous thromboembolism, stroke, MI),Carcinoma of the breast and reproductive organs,Hepatic disease (adenoma, hepatocellular carcinoma),Ocular lesions (retinal thrombosis),Gallbladder disease,Carbohydrate and lipid effects,Elevated blood pressure,Headache/migraine,Bleeding irregularities,Depression,Hereditary angioedema,Chloasma,Hepatic function impairment,Iron supplementation (Fe fumarate): may cause GI upset, constipation, and dark stools
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy or suspected pregnancy,Benign or malignant liver tumor,Active liver disease,Hypersensitivity to any component,Smoking in women >35 years
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No significant food interactions. However, grapefruit juice may inhibit CYP3A4 metabolism and theoretically increase estrogen levels, but clinical significance is undetermined. Avoid St. John's wort, which reduces contraceptive efficacy. Caffeine metabolism may be decreased, leading to increased caffeine effects. No specific dietary restrictions required.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: Increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestin component. Second and third trimesters: Risk of fetal feminization (masculinization of female fetuses) from androgen-like effects of progestin; also associated with increased risk of neonatal hepatoblastoma and possibly other tumors. Combination hormonal contraceptives should be discontinued immediately if pregnancy occurs.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Excreted in breast milk in small amounts (estrogen and progestin). M/P ratio not well-defined. Use may reduce milk production and quality, especially in early postpartum period. Consider alternative contraception during breastfeeding, especially in first 6 months. Use only if benefits outweigh risks, with close monitoring of infant growth and development.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
Contraindicated in pregnancy; no dose adjustments indicated as use is not recommended. If inadvertently taken during pregnancy, discontinue immediately. No dosage changes are suggested for postpartum use, but alternative contraception should be considered during breastfeeding.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
Gildess FE 1/20 is a monophasic oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate with ferrous fumarate placebos. It is indicated for contraception and may be used off-label for acne. The low estrogen dose may lead to more breakthrough bleeding, especially in the first few cycles. Advise patients to take at the same time daily and not to skip active pills. The iron in placebos can cause dark stools; warn patients. Missed pill management: if one active pill is missed, take it as soon as remembered; if two are missed, take two and use backup contraception for 7 days. Consider CYP3A4 inducers (e.g., rifampin, certain anticonvulsants) which reduce efficacy. Not recommended in patients with BMI > 35 due to increased failure risk. Do not use in smokers over 35 years old. Monitor blood pressure and for thrombotic events.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one pill daily at the same time, even during withdrawal bleed weeks.,If you miss a pill, follow the package instructions: take the missed pill immediately and continue; if more than one missed, use backup contraception for 7 days.,The last 7 pills in the pack are placebo; they contain iron, so do not skip them but they don't provide contraceptive protection.,Iron in placebos may cause dark stools; this is harmless.,Common side effects: nausea, breast tenderness, headache, breakthrough bleeding (especially first 3 months). These often improve with time.,Contact your doctor if you have severe abdominal pain, chest pain, shortness of breath, severe headaches, vision changes, or leg pain/swelling.,This pill does not protect against sexually transmitted infections (STIs). Use condoms for STI prevention.,Avoid smoking while taking this medication, especially if over 35 years old.,Tell your doctor about all medications, especially antibiotics, antifungals, and seizure medications, as they may decrease effectiveness.,If you are undergoing surgery, inform your surgeon you are taking this pill.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GILDESS FE 1/20 vs ADQUEY, answered by our medical review team.
GILDESS FE 1/20 is a Oral Contraceptive that works by Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release; norethindrone induces progestational changes in endometrium and cervical mucus, preventing ovulation and fertilization.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GILDESS FE 1/20 and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GILDESS FE 1/20 is: One tablet orally once daily for 21 days followed by 7 placebo tablets per 28-day cycle.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GILDESS FE 1/20 and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GILDESS FE 1/20 is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: Increased risk of neural tube defects, congenital heart defects, and limb reducti. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.